Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN) gapped down before the market opened on Thursday . The stock had previously closed at $11.21, but opened at $10.66. Valneva shares last traded at $10.56, with a volume of 4,868 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of Valneva from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Valneva Stock Up 1.2%

The company has a quick ratio of 1.36, a current ratio of 1.78 and a debt-to-equity ratio of 0.72. The business has a 50-day simple moving average of $10.18 and a 200-day simple moving average of $9.61. The company has a market cap of $913.63 million, a PE ratio of -7.37 and a beta of 1.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in VALN. Frazier Life Sciences Management L.P. acquired a new stake in Valneva in the 2nd quarter valued at $8,240,000. JPMorgan Chase & Co. acquired a new position in Valneva during the third quarter worth $124,000. XTX Topco Ltd acquired a new position in Valneva during the fourth quarter worth $94,000. Marex Group plc purchased a new position in Valneva during the second quarter valued at $64,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Valneva during the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.